• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Scopus
  4. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19
 
  • Details
  • Full
Options
2023
Journal Article
Title

Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19

Abstract
Much of the global population now has some level of adaptive immunity to SARS-CoV-2 induced by exposure to the virus (natural infection), vaccination, or a combination of both (hybrid immunity). Key questions that subsequently arise relate to the duration and the level of protection an individual might expect based on their infection and vaccination history. A multi-component composite correlate of risk (CoR) could inform individuals and stakeholders about protection and aid decision making. This perspective evaluates the various elements that need to be accommodated in the development of an antibody-based composite CoR for reinfection with SARS-CoV-2 or development of severe COVID-19, including variation in exposure dose, transmission route, viral genetic variation, patient factors, and vaccination status. We provide an overview of antibody dynamics to aid exploration of the specifics of SARS-CoV-2 antibody testing. We further discuss anti-SARS-CoV-2 immunoassays, sample matrices, testing formats, frequency of sampling and the optimal time point for such sampling. While the development of a composite CoR is challenging, we provide our recommendations for each of these key areas and highlight areas that require further work to be undertaken.
Author(s)
Holdenrieder, Stefan
Technische Universität München
Dos Santos Ferreira, Carlos Eduardo
Hospital Israelita Albert Einstein
Izopet, Jacques
CHU de Toulouse
Theel, Elitza S.
Mayo Clinic
Wieser, Andreas
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
Journal
Frontiers in Public Health
Funder
Roche  
Open Access
DOI
10.3389/fpubh.2023.1290402
Additional link
Full text
Language
English
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP  
Keyword(s)
  • antibodies

  • clinical utility

  • immunity

  • innate and adaptive immune response

  • models and modeling

  • patient-centered care

  • SARS-CoV-2

  • vaccines

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024